Penserra Capital Management LLC Makes New $2.31 Million Investment in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Penserra Capital Management LLC purchased a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 28,818 shares of the company’s stock, valued at approximately $2,308,000. Penserra Capital Management LLC owned 0.06% of PROCEPT BioRobotics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Values First Advisors Inc. bought a new stake in PROCEPT BioRobotics in the third quarter valued at about $27,000. Mark Sheptoff Financial Planning LLC bought a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at about $36,000. Quest Partners LLC raised its position in shares of PROCEPT BioRobotics by 2,492.3% in the 2nd quarter. Quest Partners LLC now owns 674 shares of the company’s stock valued at $41,000 after acquiring an additional 648 shares during the period. Nisa Investment Advisors LLC boosted its stake in PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock worth $89,000 after acquiring an additional 713 shares during the last quarter. Finally, Sentry Investment Management LLC acquired a new position in PROCEPT BioRobotics during the third quarter valued at approximately $120,000. 89.46% of the stock is currently owned by institutional investors.

Insider Activity at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 25,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total transaction of $1,811,750.00. Following the completion of the transaction, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at approximately $6,964,077.12. This represents a 20.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Antal Rohit Desai sold 33,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $96.60, for a total value of $3,187,800.00. Following the transaction, the director now directly owns 231,363 shares in the company, valued at $22,349,665.80. This trade represents a 12.48 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 561,773 shares of company stock valued at $49,073,125. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Stock Up 4.5 %

PRCT stock opened at $97.78 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The stock has a market capitalization of $5.10 billion, a P/E ratio of -50.14 and a beta of 1.01. PROCEPT BioRobotics Co. has a fifty-two week low of $33.45 and a fifty-two week high of $103.81. The business has a 50-day moving average of $82.41 and a 200-day moving average of $72.62.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $58.40 million during the quarter, compared to the consensus estimate of $53.30 million. During the same quarter in the prior year, the firm posted ($0.51) EPS. The b